Jazz Pharmaceuticals (JAZZ) Receives a Hold from Mizuho Securities


Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Jazz Pharmaceuticals (JAZZ) today. The company’s shares closed yesterday at $128.65.

Rivkind Koffler observed:

“We reiterate our Neutral rating, but raise PT to $148 from $146 previously.”

According to TipRanks.com, Koffler is a 3-star analyst with an average return of 1.0% and a 39.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.

Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $174.55.

See today’s analyst top recommended stocks >>

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $159 million. In comparison, last year the company had a net profit of $45.99 million.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts